Intralesional Axitinib Injection Mitigates Hypertrophic Scar by Inhibiting Angiogenesis Pathway: A Preliminary Study in a Rabbit Ear Model

References

• Lee HJ, Jang YJ. Recent understandings of biology, prophylaxis and treatment strategies for hypertrophic scars and keloids. Int J Mol Sci. 2018;19(3):1. doi:10.3390/ijms19030711
   Web of Science ®Google Scholar
• Hsu KC, Luan CW, Tsai YW. Review of silicone gel sheeting and silicone gel for the prevention of hypertrophic scars and keloids. Wounds. 2017;29(5):154–158.
   PubMed Web of Science ®Google Scholar
• Seago M, Shumaker PR, Spring LK, et al. Laser treatment of traumatic scars and contractures: 2020 international consensus recommendations. Lasers Surg Med. 2020;52(2):96–116doi:10.1002/lsm.23201
   PubMed Web of Science ®Google Scholar
• Lv K, Liu H, Xu H, et al. Ablative fractional CO(2) laser surgery improving sleep quality, pain and pruritus in adult hypertrophic scar patients: a prospective cohort study. Burns Trauma. 2021;9:tkab023. doi:10.1093/burnst/tkab023
   PubMed Web of Science ®Google Scholar
• Ledon JA, Savas J, Franca K, Chacon A, Nouri K. Intralesional treatment for keloids and hypertrophic scars: a review. Dermatol Surg. 2013;39(12):1745–1757. doi:10.1111/dsu.12346
   PubMed Web of Science ®Google Scholar
• Mony MP, Harmon KA, Hess R, Dorafshar AH, Shafikhani SH. An updated review of hypertrophic scarring. Cells. 2023;12(5):678. doi:10.3390/cells12050678
   PubMed Web of Science ®Google Scholar
• Ogawa R. The most current algorithms for the treatment and prevention of hypertrophic scars and keloids: a 2020 update of the algorithms published 10 years ago. Plast Reconstr Surg. 2022;149(1):79e–94e. doi:10.1097/PRS.0000000000008667
   PubMed Web of Science ®Google Scholar
• DiPietro LA. Angiogenesis and wound repair: when enough is enough. J Leukoc Biol. 2016;100(5):979–984. doi:10.1189/jlb.4MR0316-102R
   PubMed Web of Science ®Google Scholar
• Gurtner GC, Werner S, Barrandon Y, Longaker MT. Wound repair and regeneration. Nature. 2008;453(7193):314–321. doi:10.1038/nature07039
   PubMed Web of Science ®Google Scholar
• Ogawa R, Akaishi S. Endothelial dysfunction may play a key role in keloid and hypertrophic scar pathogenesis - Keloids and hypertrophic scars may be vascular disorders. Med Hypotheses. 2016;96:51–60. doi:10.1016/j.mehy.2016.09.024
   PubMed Web of Science ®Google Scholar
• Wilgus TA. Vascular endothelial growth factor and cutaneous scarring. Adv Wound Care. 2019;8(12):671–678. doi:10.1089/wound.2018.0796
   Web of Science ®Google Scholar
• Song Y, Dai F, Zhai D, et al. Usnic acid inhibits breast tumor angiogenesis and growth by suppressing VEGFR2-mediated AKT and ERK1/2 signaling pathways. Angiogenesis. 2012;15(3):421–432. doi:10.1007/s10456-012-9270-4
   PubMed Web of Science ®Google Scholar
• Wilgus TA, Ferreira AM, Oberyszyn TM, Bergdall VK, Dipietro LA. Regulation of scar formation by vascular endothelial growth factor. Lab Invest. 2008;88(6):579–590. doi:10.1038/labinvest.2008.36
   PubMed Web of Science ®Google Scholar
• Tanimoto T, Jin ZG, Berk BC. Transactivation of vascular endothelial growth factor (VEGF) receptor Flk-1/KDR is involved in sphingosine 1-phosphate-stimulated phosphorylation of Akt and endothelial nitric-oxide synthase (eNOS). J Biol Chem. 2002;277(45):42997–43001. doi:10.1074/jbc.M204764200
   PubMed Web of Science ®Google Scholar
• Shiojima I, Walsh K. Role of Akt signaling in vascular homeostasis and angiogenesis. Circ Res. 2002;90(12):1243–1250. doi:10.1161/01.RES.0000022200.71892.9F
   PubMed Web of Science ®Google Scholar
• Gao L, Nadora DM, Phan S, et al. Topical axitinib suppresses angiogenesis pathways induced by pulsed dye laser. Br J Dermatol. 2015;172(3):669–676. doi:10.1111/bjd.13439
   PubMed Web of Science ®Google Scholar
• DiPietro LA. Angiogenesis and scar formation in healing wounds. Curr Opin Rheumatol. 2013;25(1):87–91. doi:10.1097/BOR.0b013e32835b13b6
   PubMed Web of Science ®Google Scholar
• Jayson GC, Kerbel R, Ellis LM, Harris AL. Antiangiogenic therapy in oncology: current status and future directions. Lancet. 2016;388(10043):518–529.
   PubMed Web of Science ®Google Scholar
• Chen J, Ding X, Du W, Tang X, Yu WZ. Inhibition of corneal neovascularization by topical application of nintedanib in rabbit models. Int J Ophthalmol. 2021;14(11):1666–1673. doi:10.18240/ijo.2021.11.04
   PubMed Web of Science ®Google Scholar
• Spigel DR, Rubin MS, Gian VG, et al. Sorafenib and continued erlotinib or sorafenib alone in patients with advanced non-small cell lung cancer progressing on erlotinib: a randomized Phase II study of the Sarah Cannon Research Institute (SCRI). Lung Cancer. 2017;113:79–84. doi:10.1016/j.lungcan.2017.09.007
   PubMed Web of Science ®Google Scholar
• Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006;368(9544):1329–1338.
   PubMed Web of Science ®Google Scholar
• Ma D, Chen L, Shi J, et al. Pigment epithelium-derived factor attenuates angiogenesis and collagen deposition in hypertrophic scars. Wound Repair Regen. 2020;28(5):684–695. doi:10.1111/wrr.12828
   PubMed Web of Science ®Google Scholar
• Hu-Lowe DD, Zou HY, Grazzini ML, et al. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res. 2008;14(22):7272–7283. doi:10.1158/1078-0432.CCR-08-0652
   PubMed Web of Science ®Google Scholar
• Gross-Goupil M, Francois L, Quivy A, Ravaud A. Axitinib: a review of its safety and efficacy in the treatment of adults with advanced renal cell carcinoma. Clin Med Insights Oncol. 2013;7:269–277. doi:10.4137/CMO.S10594
   PubMedGoogle Scholar
• Morris DE, Wu L, Zhao LL, et al. Acute and chronic animal models for excessive dermal scarring: quantitative studies. Plast Reconstr Surg. 1997;100(3):674–681. doi:10.1097/00006534-199709000-00021
   PubMed Web of Science ®Google Scholar
• Li J, Wang J, Wang Z, et al. Experimental models for cutaneous hypertrophic scar research. Wound Repair Regen. 2020;28(1):126–144. doi:10.1111/wrr.12760
   PubMed Web of Science ®Google Scholar
• Lledo Riquelme M, Campos-Mollo E, Fernandez-Sanchez L. Topical axitinib is a potent inhibitor of corneal neovascularization. Clin Exp Ophthalmol. 2018;46(9):1063–1074. doi:10.1111/ceo.13333
   PubMed Web of Science ®Google Scholar
• Thompson CM, Sood RF, Honari S, Carrougher GJ, Gibran NS. What score on the Vancouver Scar Scale constitutes a hypertrophic scar? Results from a survey of North American burn-care providers. Burns. 2015;41(7):1442–1448. doi:10.1016/j.burns.2015.04.018
   PubMed Web of Science ®Google Scholar
• Wang D, Stockard CR, Harkins L, et al. Immunohistochemistry in the evaluation of neovascularization in tumor xenografts. Biotech Histochem. 2008;83(3–4):179–189. doi:10.1080/10520290802451085
   PubMed Web of Science ®Google Scholar
• Kim S, Choi TH, Liu W, Ogawa R, Suh JS, Mustoe TA. Update on scar management: guidelines for treating Asian patients. Plast Reconstr Surg. 2013;132(6):1580–1589. doi:10.1097/PRS.0b013e3182a8070c
   PubMed Web of Science ®Google Scholar
• Keating GM. Axitinib: a review in advanced renal cell carcinoma. Drugs. 2015;75(16):1903–1913. doi:10.1007/s40265-015-0483-x
   PubMed Web of Science ®Google Scholar
• Kwak DH, Bae TH, Kim WS, Kim HK. Anti-vascular endothelial growth factor (Bevacizumab) therapy reduces hypertrophic scar formation in a rabbit ear wounding model. Arch Plast Surg. 2016;43(6):491–497. doi:10.5999/aps.2016.43.6.491
   PubMedGoogle Scholar
• Song Y, Yu Z, Song B, et al. Usnic acid inhibits hypertrophic scarring in a rabbit ear model by suppressing scar tissue angiogenesis. Biomed Pharmacother. 2018;108:524–530. doi:10.1016/j.biopha.2018.06.176
   PubMed Web of Science ®Google Scholar
• Ren HT, Hu H, Li Y, Jiang HF, Hu XL, Han CM. Endostatin inhibits hypertrophic scarring in a rabbit ear model. J Zhejiang Univ Sci B. 2013;14(3):224–230. doi:10.1631/jzus.B1200077
   PubMed Web of Science ®Google Scholar
• Tan W, Jia W, Sun V, Mihm MC, Nelson JS. Topical rapamycin suppresses the angiogenesis pathways induced by pulsed dye laser: molecular mechanisms of inhibition of regeneration and revascularization of photocoagulated cutaneous blood vessels. Lasers Surg Med. 2012;44(10):796–804. doi:10.1002/lsm.22101
   PubMed Web of Science ®Google Scholar